Dynamic ordering design for dose finding in drug-combination trials.
暂无分享,去创建一个
[1] Ying Yuan,et al. BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. , 2011, The annals of applied statistics.
[2] R Simon,et al. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Adrian P Mander,et al. A product of independent beta probabilities dose escalation design for dual-agent phase I trials , 2015, Statistics in medicine.
[4] X. Paoletti,et al. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] John O'Quigley,et al. Continual Reassessment Method for Partial Ordering , 2011, Biometrics.
[6] G. Rosner,et al. Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee , 2014, Clinical Cancer Research.
[7] Ying Yuan,et al. A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents , 2009, Biometrics.
[8] Guosheng Yin,et al. Nonparametric overdose control with late-onset toxicity in phase I clinical trials. , 2017, Biostatistics.
[9] S. Zohar,et al. Competing designs for drug combination in phase I dose‐finding clinical trials , 2015, Statistics in medicine.
[10] A. Venook,et al. Design Issues in Dose-Finding Phase I Trials for Combinations of Two Agents , 2009, Journal of biopharmaceutical statistics.
[11] Guosheng Yin,et al. Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials , 2016 .
[12] Guosheng Yin,et al. Bayesian optimal interval design for dose finding in drug-combination trials , 2017, Statistical methods in medical research.
[13] G. Yin,et al. Non‐parametric overdose control for dose finding in drug combination trials , 2019, Journal of the Royal Statistical Society: Series C (Applied Statistics).
[14] W. M. Smit,et al. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer , 2015, Investigational New Drugs.
[15] Anastasia Ivanova,et al. Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.
[16] Ying Yuan,et al. Bayesian dose finding in oncology for drug combinations by copula regression , 2009 .
[17] M. Sznol,et al. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies , 2016, Cancer Chemotherapy and Pharmacology.
[18] Kai Wang,et al. A non‐parametric approach to the design and analysis of two‐dimensional dose‐finding trials , 2004, Statistics in medicine.
[19] Ying Yuan,et al. Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.
[20] Peter F Thall,et al. Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.
[21] Michael J. Sweeting,et al. Adaptive designs for dual-agent phase I dose-escalation studies , 2013, Nature Reviews Clinical Oncology.
[22] J. Leeuw,et al. Isotone Optimization in R: Pool-Adjacent-Violators Algorithm (PAVA) and Active Set Methods , 2009 .
[23] Alexia Iasonos,et al. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Ying Yuan,et al. Bayesian optimal interval designs for phase I clinical trials , 2015, Journal of the Royal Statistical Society: Series C (Applied Statistics).
[25] Ying Yuan,et al. A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model , 2014, Pharmaceutical statistics.
[26] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[27] A Kramar,et al. Continual reassessment methods in phase I trials of the combination of two drugs in oncology. , 1999, Statistics in medicine.